NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Seres Therapeutics, Inc. (MCRB) Stock Analysis

Seres Therapeutics, Inc. (MCRB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MCRB

$2.30

−$0.01 (−0.43%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MCRB with… →

MCRB Key Statistics

As of Oct 21, 2026
Trading
Open
$2.30
Previous Close
$2.31
Day's Range
2.26–2.40
52-Week Range
2.26–29.98
Volume
41.77K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.31
Valuation
Market Cap
$23.10M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.27
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.42
Financials (FY)
Revenue (FY)
$789.00K
Net Income (FY)
$5.70M+4,088.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.04M
1-Year Return
−87.74%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
64.29K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MCRB closed at $2.30, −87.74% over 1 year.

Seres Therapeutics, Inc. (MCRB) has a market capitalization of $23.10M.

In fiscal 2025, MCRB reported revenue of $789.00K.

MCRB Stock Return by Calendar Year

Seres Therapeutics, Inc. (MCRB) 10-year return: what $10,000 became

1 year
$10,000 $1,226
−87.74%
5 years
$10,000 $189
−98.11%
10 years
$10,000 $93
−99.07%

If you had invested $10,000 in Seres Therapeutics, Inc. (MCRB) 10 years ago, at the close on October 21, 2016, it would have been worth $93 at the close on October 21, 2026: −99.07% in total, −37.34% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−84.54%
2025−10.47%
2024−40.64%
2023−75.00%
2022−32.77%
2021−66.00%
2020+610.14%
2019−23.67%
2018−55.42%
2017+2.42%
2016 (partial year)+2.17%

As of October 21, 2026.

MCRB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$789.00K$5.70M721.9%
2024$0.00$136.00K—
2023$0.00−$113.72M—
2022$0.00−$250.16M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$789.00K−$5.76M−$93.97M$5.70M721.9%
2024$0.00−$3.53M−$121.32M$136.00K—
2023$0.00$0.00−$195.10M−$113.72M—
2022$0.00$0.00−$179.91M−$250.16M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MCRB Valuation vs Biotechnology Median

Median of 608 stocks
MetricMCRBBiotechnology medianvs median
P/S ratio12.2713.308% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Seres Therapeutics, Inc. (MCRB) carries a market capitalisation of $23.10M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 66.

MCRB last closed at $2.30 on October 21, 2026. That is −$0.01 (−0.43%) against the previous close. The 52-week range on file runs from $2.26 to $29.98. The latest close sits 1.73% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $789.00K. The same year closed with net income of $5.70M. That is +4,088.24% against the prior fiscal year. Earnings per share on a trailing basis come to −2.42.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $789.00K in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 12.27 times revenue. On price-to-sales that is 7.74% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 0.31. Annualized volatility over the trailing 10 years is 152.8%. The trailing one-year total return is −87.74%. Measured over 10 years, that is −37.34% a year compounded.

Growth & Income

No dividend is on file for MCRB.

2026 is still running; the total return is −84.54% year to date. Across the complete calendar years on file, 2020 returned +610.14% and 2023 returned −75.00%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Seres Therapeutics, Inc. (MCRB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Seres Therapeutics, Inc. MCRB $23.10M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Seres Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Visit website →